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SUMMARY Immunohistochemical expression of MAGE-A1, MAGE-A3/4 
and NY-ESO-1/LAGE-1 cancer testis antigens (CTA) was assessed in 24 
fetal testes from 15th to 36th week of gestation. Three monoclonal antibodies 
were used for immunohistochemical staining: 77B recognizing MAGE-A1, 
57B recognizing multiple MAGE-A CTA, and D8.38 recognizing NY-ESO-1/
LAGE-1. Expression of MAGE-A1 was not observed in fetal testis samples, 
whereas multi-MAGE-A and NY-ESO-1/LAGE-1 specific reagents stained 
pro-spermatogonia in all samples with different expression levels during 
the period of fetal development observed. Significant expression of MAGE-
A3/4 and almost continuous expression of NY-ESO-1 in fetal testes after 
22nd week of gestation suggested their important role in the development of 
sex cords and pro-spermatogonia in particular.
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IntRodUCtIon
 Cancer testis antigens (CTA) are proteins ex-
pressed in a limited number of healthy tissues and 
in a large variety of tumors of unrelated histologic 
origin (1). In normal tissue, their expression has 
been detected in adult testis germ cells and pla-
centa (2). Their biological function remains un-
known, although indications for their involvement 
in the regulation of gene expression have been re-
ported (3). Notably, they are able to induce humor-
al and cellular immune responses and therefore a 
number of them have been under evaluation as 
vaccines in the active specific tumor immunother-
apy (4,5). 
 The generation of specific monoclonal antibod-
ies (mAb) has permitted identification of CTA at 
the protein level in a number of tissue samples by 
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a relatively simple, inexpensive and fast method. 
In this study, we investigated the expression of 
CTA in fetal testis tissue, with the aim to improve 
the knowledge of MAGEs and NY-ESO-1 protein 
expression in developing testes.
MAteRIAlS And MethodS
 tissue samples
 Twenty four fetal testes from 15th to 36th week 
of gestation were investigated. All samples were 
obtained during routine pedopathologic section 
after spontaneous abortions at University Depart-
ment of Gynecology and Obstetrics, Zagreb Uni-
versity Hospital Center. Developmental age of the 
fetuses was determined by data on the last period 
and from autopsy data, e.g., crown-rump length, 
crown-heel length, femur and humerus length.
  histology
 The testis tissue samples were fixed in Bouin’s 
fluid, dehydrated and embedded in paraffin. Paraf-
fin blocks were cut into sections for hematoxylin-
eosin (H+E) and immunohistochemical staining.
 Immunohistochemistry
 Tissue sections of 3-5 μm thickness were cut 
from paraffin embedded tissue blocks and placed 
on object slides (Menzel-Glaser, Germany). Slides 
with tissue sections were incubated for 20 min-
utes in a thermostat at 60 °C. Sections were then 
deparaffinized and incubated for 3x5 minutes in 
10 mmol/L citrate buffer (pH 6.0) in a microwave 
oven at 800 W power. Subsequently, tissue slides 
were washed with PBS buffer (pH 7.2) and the en-
dogenous peroxidase activity was blocked by a 5-
min treatment with H2O2 (Dako-No.S2023). Slides 
were then washed with PBS buffer and incubated 
for 90 minutes with 77B, 57B, or D8.38 undiluted 
supernatant at room temperature.
 After wash in PBS buffer, the secondary bioti-
nylated antibody (Dako-No. K0690) was added for 
30-min incubation. Slides were then washed with 
PBS buffer and treated with streptavidin-horserad-
ish peroxidase (Dako-No. K0690) for 30 minutes. 
Tissue sections were washed once more in PBS 
buffer and then chromogen (Dako-No. K3468) 
was added for 5 minutes. Slides were washed in 
distilled water, stained with hemalaun (Dako-No. 
S2020) for 1 minute, washed with water, dehydrat-
ed with alcohol (96%), cleared with xylene, and 
mechanically covered.
 Melanoma expressing CTA and adult testis tis-
sues were used as positive control throughout the 
study, whereas stroma and unstained cells served 
as negative control. Immunohistochemistry stain-
ing results were semiquantitatively expressed as 
follows: 1) negative response (-): no staining in 
germ cells; 2) weak positive response (+): up to 
10% of germ cells positive; 3) moderate positive 
response (++): 11%-50% of germ cells positive; 
and 4) strong positive response (+++): over 50% 
of germ cells positive.
 The study was approved by the Ethics Commit-
tee of the Zagreb University Hospital Center and 
Ethics Committee of the School of Medicine, Uni-
versity of Zagreb.
ReSUltS
 The fetal testes under investigation consisted 
of two major parts: sex cords and interstitial com-
partment, i.e. stroma. Sex cords measured 40-50 
μm and were limited by several layers of peritu-
bular cells and lined with pro-spermatogonia and 
fetal Sertoli cells. Pro-spermatogonia were rec-
ognized by their abundant and pale-stained cyto-
plasm. Their nucleus was large, ovoid or round, 
with abundant euchromatin and clumps of hetero-
chromatin, predominantly associated with nuclear 
envelope. Frequently, one or more prominent nu-
cleoli could be noted within the nuclei of the cells. 
Figure 1. Human fetal testis in 18th week of gesta-
tion. Sex cords (arrows) are surrounded by layers 
of peritubular cells and lined with pro-spermato-
gonia and Sertoli cells. Some pro-spermatogonia 
(recognized by their size and abundant cytoplasm) 
highly express MAGE-A3/4. Sertoli cells show no 
positivity. The testis interstitium (TI) is composed 
of loose connective tissue with blood vessels (ar-
rowheads). Leydig cells of the interstitium are 
negative for MAGE-A3/4. (DAB and hematoxylin 
staining, X200, scale bar = 100µm)
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Sertoli cells were distinguished by their smaller 
size (when compared to pro-spermatogonia), 
scanty cytoplasm, and round or ovoid nucleus. 
Within the interstitium of the gonad, fetal Leydig 
cells appeared in 2 forms. One cell type was oval, 
with centrally or eccentrically positioned nucleus 
and sometimes well-visible nucleolus, whereas 
another cell type was elongated with round or oval 
nucleus situated mainly in the middle of the cell. 
Other loosely arranged connective tissue cells in-
cluding small blood vessels contributed to the in-
terstitial compartment of the human fetal testis. In 
general, sex cords and associated blood vessels 
in the interstitium grew progressively from 15th to 
36th week of gestation, achieving rather tortuous 
structures.
 The expression of MAGE-A1 CTA as detected 
by 77B mAb was always negative in our samples, 
whereas multi MAGE-A specific, 57B and NY-
ESO-1/LAGE-1 specific D8.38 mAbs stained pro-
spermatogonia throughout the gestational period 
under investigation (Figs. 1 and 2). Both antibod-
ies stained the cytoplasm of pro-spermatogonia, 
whereas no positive signal was found in Sertoli or 
peritubular cells of sex cords. It should be pointed 
out that not all pro-spermatogonia within the indi-
vidual sex cords were positive at various gesta-
tional weeks, but only a fraction of them (Figs. 1 
and 2). In addition, no positive cells were found in 
the interstitium of the gonad. Leydig cells as well 
as other interstitial cells including blood vessels 
were negative.  
 The MAGE-A3/4 positivity was uneven dur-
ing fetal development. It was present starting at 
16th week, the earliest time point evaluated, and 
it slightly increased until 26th week. Thereafter, 
MAGE-A expression decreased, albeit never be-
low the ++ level of positivity with a nadir at 33rd 
week. Then it roused again towards the end of 
fetal development. In contrast to MAGE-A, NY-
ESO-1/LAGE-1 expression was initially detected 
with higher intensity and reached its maximum at 
24th week. This level remained constant through-
out fetal development (Fig. 3).
Figure 2. Part of human fetal testis in 25th week 
of development; expression of NY-ESO-1/LAGE-
1.  Some sex cords (arrows) contain immunoposi-
tive pro-spermatogonia. The testis interstitium (TI) 
demonstrates no positive cells. Blood vessels (ar-
rowheads). Tunica albuginea (TA). (DAB and he-
matoxylin staining, X200, scale bar = 100µm)
Figure 3. Distribution of MAGE-A and NY-ESO-
1/LAGE-1 expression in fetal testes during gesta-
tion.  
dISCUSSIon
 It has been shown that human fetal germ cells 
are heterogeneous regarding their morphology 
and production of different proteins. It has also 
been suggested that CTA are involved in the de-
velopment and differentiation of fetal germ cells. 
The aim of the study was to improve our knowl-
edge of MAGEs and NY-ESO-1 protein expres-
sion in developing testes. 
 We detected CTA expression only in pro-sper-
matogonia, as previously observed (6). MAGE-
A1 expression was negative in all our samples. 
Gjerstorff et al. observed a bimodal pattern of ex-
pression with high MAGE-A1 expression in the 9th 
week of development, subsequently decreasing 
until 16th week (7). Then it started to be strongly 
expressed until 21st week, slightly dropping there-
after. The discrepancy with our results could be 
explained by the use of a different antibody (MA 
454), which in our previous work with tumor sam-
ples displayed a stronger positivity as compared to 
77B (8). Pauls et al. using the same mAb 57B as in 
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our study found only a few germ cells to express 
MAGE-A at week 12/13. The expression was then 
continuously increasing during further develop-
ment, reaching 50% of germ cells at week 24 and 
more than 90% in the testis of the neonate (9). Our 
results are consistent with the high expression of 
MAGE-A in 26th week, slightly decreasing until 33rd 
week and then rising again towards maximum lev-
els. These data are also consistent with a bimodal 
timing of MAGE-A CTA expression, see above. 
 Satie et al. found no NY-ESO-1 staining in im-
mature gonad (before 16th week of gestation), with 
an increased number of positive cells in 18th week 
and maximum in 40-week-old fetus (10).
 We showed the expression of NY-ESO-1/
LAGE-1 to reach maximum level in 20th week, 
then maintaining it until the end of development. 
The constantly high level of NY-ESO-1 expression 
underlines its putatively important function during 
the second half of fetal development of pro-sper-
matogonia. On the other hand, no staining was 
found in fetal Sertoli and Leydig cells, or in the 
cells of connective tissue, as previously described 
(10).
 Our immunohistochemical study showed miss-
ing expression of MAGE-A1, a bimodal expres-
sion of MAGE-A, and an almost constantly strong 
expression of NY-ESO-1/LAGE-1 CTA after 20th 
week of fetal testis development, suggesting that 
these proteins might play an important role in the 
pro-spermatogonia development. 
 Detection of CTA expression in fetal gonads as 
well as in gonads after birth on the one hand, and 
in different tumors in humans on the other hand, 
shows that these proteins could be responsible for 
some common characteristics of gonad cells and 
cancer cells. There is a possibility that cancer is 
re-expressing CTA in order to achieve some of the 
characteristics that can help it grow and advance. 
The re-expression of CTA in cells may be related 
to immortalization, invasion, lack of adhesion and 
migratory behavior of the cells as well as to de-
methylation and downregulation of MHC. Due to 
a significant number of proteins in CTA family, it is 
not easy to investigate their exact function in de-
veloping and adult testes. However, prolonged and 
strong expression of NY-ESO-1 from the begin-
ning of second trimester till the end of pregnancy 
indicates that this protein has a general function in 
developing germ cells. Its function is probably not 
associated with a specific developmental stage in 
germ cell differentiation, as it may be the case with 
MAGE-A which showed bimodal distribution (11).
 Our immunohistochemistry data show that 
both MAGE-A3/4 and NY-ESO-1/LAGE-1 are ex-
pressed in some pro-spermatogonia, while at the 
same time a large number of these cells are nega-
tive. The reason for this could lie in different phas-
es of maturation. Although looking much alike, 
some of these cells could be either in ‘silent’ mode 
(expression of MAGE-A3/4 and NY-ESO-1/LAGE-
1 genes is switched off) or strongly expressing the 
afore-mentioned antigens, as described in the re-
sults of the present study. 
ConClUSIon
 Thus, pro-spermatogonia (although morpho-
logically a homogeneous cell type within fetal sex 
cords) can be postulated to form an inhomoge-
neous population of cells regarding their matura-
tion phase and gene expression. 
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